Pilot Study for SmartWatch-driven AF Detection in Stroke Patients

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Unrecognized atrial fibrillation (AF) is a common cause of ischemic stroke. Implantable event monitors (ICM) are the gold standard for continuous heart rhythm monitoring but they have been implemented in very few patients after stroke due to high invasiveness and high costs. In this trial, patients with implanted ICMs (Medtronic Reveal LINQ Insertable Cardiac Monitor) will be randomized to use one of two wearables (1:1 Apple Watch or PulseOn) for continuous monitoring. The aim is to compare the probability of detecting an episode of AF with a wearable versus the gold standard ICM. Both groups will use the wearable for 12 weeks. If the wearables detect an arrhythmic pulse curve, this is communicated by vibration. By laying the other hand on the device, a 1-channel ECG is performed. ECG data will be transferred regularly to the CoreLab (Universityhospital Leipzig) for analysis. After 12 weeks, the patients will visit the site and answer questions regarding the usability, compliance and satisfaction with the wearables.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: f
View:

• Study participation in Find-AF 2

• Randomization in the intervention arm of the Find-AF 2 study and presence of an implanted event recorder (Medtronic Reveal LINQTM Insertable Cardiac Monitor)

• Signed informed consent

• All inclusion criteria of the Find-AF 2 study are met (according to protocol version Final 4.0, dated 08.05.2024):

• i. Recent symptomatic ischemic stroke within the last 30 days (sudden focal neurologic deficit lasting \> 24 h consistent with the territory of a cerebral artery) If the neurologic deficit lasted \< 24 h a corresponding lesion\* on brain imaging is needed.

⁃ ii. Age ≥ 60 years. iii. Patient without or with only slight disability (modified Rankin Scale score ≤ 2) before onset of stroke-related symtoms.

⁃ iv. Written informed consent

⁃ \* Corresponding lesion can be an acute lesion on diffusion-weighted magnetic resonance imaging, native computed tomography (CT) or CT perfusion imaging or a recent occlusion or intracranial thrombus on angiography (CTA, MRA, DSA)

Locations
Other Locations
Germany
Evangelisches Klinikum Bethel, Clinic for Neurology
RECRUITING
Bielefeld
University of Essen, Clinic of Neurology
NOT_YET_RECRUITING
Essen
University of Göttingen, Clinic for Neurology
NOT_YET_RECRUITING
Göttingen
Krankenhaus Martha-Maria Halle-Dölau
NOT_YET_RECRUITING
Halle
University Hospital Leipzig, Clinic for Neurology
RECRUITING
Leipzig
University of Mainz, Clinic for Neurology
NOT_YET_RECRUITING
Mainz
Klinikum Nürnberg
NOT_YET_RECRUITING
Nuremberg
Kliniken Südostbayern AG, Klinikum Traunstein
RECRUITING
Traunstein
Contact Information
Primary
Rolf Wachter, Prof. Dr.
rolf.wachter@medizin.uni-leipzig.de
+49 341 97 - 20958
Time Frame
Start Date: 2025-05-15
Estimated Completion Date: 2027-03
Participants
Target number of participants: 80
Treatments
Experimental: AppleWatch
semi-continuous heart rhythm monitoring with AppleWatch~for 12 weeks
Experimental: PulseOn
semi-continuous heart rhythm monitoring with PulseOn device~for 12 weeks
Related Therapeutic Areas
Sponsors
Leads: University of Leipzig

This content was sourced from clinicaltrials.gov